Research programme: therapeutics - RELIEF THERAPEUTICS Holding

Drug Profile

Research programme: therapeutics - RELIEF THERAPEUTICS Holding

Alternative Names: DasKloster 0014-01; DasKloster 0039-01; DasKloster 0080-01; DasKloster 0182-01; DasKloster 0228-01; DasKloster 0249-01; DasKloster 0274-01; DasKloster 0501-01; DK 0051; Gonadorelin - RELIEF THERAPEUTICS; Octreotide - RELIEF THERAPEUTICS; Proadrenomedullin - RELIEF THERAPEUTICS; Valorphin - RELIEF THERAPEUTICS

Latest Information Update: 22 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator mondoBIOTECH
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Tuberculosis
  • Discontinued Liver cancer; Lung disorders; Lymphoproliferative disorders; Pseudomonal infections; Scleroderma

Most Recent Events

  • 22 Sep 2016 Preclinical development is ongoing for Tuberculosis (RELIEF THERAPEUTICS pipeline, September 2016)
  • 22 Sep 2016 Research programme: therapeutics - RELIEF THERAPEUTICS Holding is available for licensing as of 22 Sep 2016 (
  • 22 Sep 2016 Discontinued - Preclinical for Liver cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top